Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Cognition Therapeutics, Inc.: Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
Mo | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
09.05. | Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down | 1 | RTTNews | ||
09.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health | 5 | GlobeNewswire (USA) | ||
08.05. | Cognition Therapeutics GAAP EPS of -$0.14 misses by $0.04 | 5 | Seeking Alpha | ||
COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
08.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy | 64 | GlobeNewswire (Europe) | Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine's... ► Artikel lesen | |
07.05. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 6 | SEC Filings | ||
07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | 207 | GlobeNewswire (Europe) | - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's... ► Artikel lesen | |
01.04. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes | 112 | GlobeNewswire (Europe) | PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
25.03. | Cognition Therapeutics wird Ergebnisse der Alzheimer-Studie präsentieren | 3 | Investing.com Deutsch | ||
25.03. | Cognition Therapeutics to present Alzheimer's study results | 1 | Investing.com | ||
25.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 | 1 | GlobeNewswire (USA) | ||
24.03. | Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright | 1 | Investing.com | ||
20.03. | COGNITION THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
20.03. | COGNITION THERAPEUTICS INC Loss At -$33.97 Mln In Full Year | 4 | RTTNews | ||
20.03. | COGNITION THERAPEUTICS INC - 10-K, Annual Report | - | SEC Filings | ||
20.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
20.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | 109 | GlobeNewswire (Europe) | Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 99,25 | +1,79 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
CUREVAC | 3,950 | +1,23 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BIOGEN | 115,80 | +0,17 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
PALATIN TECHNOLOGIES | 0,079 | -0,13 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | -0,49 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,779 | +0,85 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
INTELLIA THERAPEUTICS | 6,774 | +0,83 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
BIO-GATE | 1,070 | 0,00 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahme/Kapitalmaßnahme
Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
03.06.2025... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,500 | +0,60 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen |